Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 30,000 shares at $101.05 ($3.1M) on 2024-03-20, disclosed to the SEC on 2024-03-22.
Scheduled sale ($3.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $101.05 | 2,113 | $214K | 7.0% |
| 2 | $101.05 | 2,113 | $214K | 7.0% |
| 3 | $102.15 | 7,109 | $726K | 23.6% |
| 4 | $102.15 | 7,109 | $726K | 23.6% |
| 5 | $103.18 | 5,778 | $596K | 19.4% |
| 6 | $103.18 | 5,778 |
| $596K |
| 19.4% |
| Total | $102.39 avg | 30,000 | $3.1M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |